Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Stretch Mark Remedies

Increase Global Productivity By Giving Eyeglasses To All In Need
Huge economic gains could be made if eyeglasses were provided to approximately 150 million people in need, according to research published today in the international public health journal, the Bulletin of the World Health Organization.
generic viagra online
Safe Kids Kansas Reminds Parents That Hot Weather And Vehicles Can Be A Deadly Combination For Kids
A few minutes might not seem like a long time, but there are circumstances when it can mean the difference between life and death. As temperatures begin to heat up, children are at a serious risk for heat stroke when left alone even for a few minutes in a closed vehicle.Last year, at least 42 children across the United States died from heatstroke caused by being left or trapped in a vehicle.
News of the day
Autism-Mitochondrial Study: Participants Needed
ASD Centers, LLC has expanded the clinical study started in the Dallas, Texas area to include other locations. This study is designed to examine mitochondrial dysfunction and how L-carnitine supplementation affects behavior, cognition, muscle strength, and health/physical traits in those with a diagnosed autism spectrum disorder (ASD).
Medical Devices

Landmark Data Presented At The British Society For Allergy And Clinical Immunology Shows Hay Fever Vaccine Could Be A Reality

New data presented at the British Society for Allergy and Clinical Immunology (BSACI) annual meeting demonstrate that Grazax® is the first tablet treatment to provide sustained disease control in patients with grass pollen rhinoconjunctivitis (hay fever) after the treatment period ended. This is the first time disease modification by sublingual allergy immunotherapy tablets has been achieved; effectively re-setting the immune system to reduce future allergic reactions to grass pollen. The pivotal Grazax GT08 study is an international randomised, parallel-group, double-blind, placebo-controlled multicentre study. Patients were randomised to receive either three years of Grazax or placebo, followed by a two year treatment-free follow up period. Throughout the study all patients had free access to symptomatic medications such as antihistamines and nasal sprays. Sneezing, watery eyes and a blocked nose are amongst the most common symptoms reported by patients with severe hay fever. All of these symptoms improved during the three years of continued treatment. Importantly, one year following discontinuation of treatment, these symptoms remained significantly reduced by 31% (sneezing), 60% (watery eyes) and 51% (blocked nose) compared to the patients who had previously received placebo tablets.1 Furthermore, the need for symptomatic medications was sustained during three years continued treatment and remained significantly reduced in the season one year after stopping treatment, thereby confirming a disease-modifying effect (pReferences 1. Durham S, et al. Sustained, disease-modifying effect of grass allergen tablet immunotherapy 1 year after completion of treatment. XXVIII Congress of the European Academy of Allergy and Clinical Immunology; poster # 333 About Grazax Grazax is a once daily fast-melting tablet which is placed under the tongue (sublingual) and is the first immunotherapy tablet to address the underlying cause of grass pollen allergy. Grazax became available for adults in January 2007 and for children aged 5 to 17 years in February 2009. Grazax is generally well tolerated, with the majority of side effects being transient, local allergic reactions, such as oral pruritus (irritation in the mouth), which was classified as mild to moderate. About the Grazax GT08 study The pivotal Grazax GT08 study is a randomised, parallel-group, double-blind, placebo-controlled multicentre study. Patients were randomised to receive either 3 years of Grazax or placebo, followed by a 2 year follow up period. Throughout the study all patients had free access to symptomatic medications. The data from the 4th year of the GT08 study is based upon a full analysis set that included 283 participants, with a history of grass pollen rhinoconjunctivitis uncontrolled by symptomatic medications The main clinical study end points were: - Rhinoconjunctivitis symptom score - Rhinoconjunctivitis medication score - Quality of Life (QoL) ALK-AbellÃö


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009